Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Opicapone Formulations in Healthy Volunteers
NCT02305277Phase 1Completed
- Sponsor
- BIAL
- Start
- Mar 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of opicapone in Parkinson's disease (PD) (6 arms), sponsored by BIAL. Primary endpoint: Maximum Observed Plasma Concentration at 48 hours. Started Mar 2014; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02305277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02305277.